Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'POOR METABOLIZER' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 76 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Tsuzuki, D; Takemi, C; Yamamoto, S; Tamagake, K; Imaoka, S; Funae, Y; Kataoka, H; Shinoda, S; Narimatsu, S
      Functional evaluation of cytochrome P450 2D6 with Gly(42)Arg substitution expressed in Saccharomyces cerevisiae

      PHARMACOGENETICS
    2. Zanger, UM; Fischer, J; Raimundo, S; Stuven, T; Evert, BO; Schwab, M; Eichelbaum, M
      Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6

      PHARMACOGENETICS
    3. Dai, D; Zeldin, DC; Blaisdell, JA; Chanas, B; Coulter, SJ; Ghanayem, BI; Goldstein, JA
      Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid

      PHARMACOGENETICS
    4. Furuta, T; Shirai, N; Takashima, M; Xiao, F; Hanai, H; Nakagawa, K; Sugimura, H; Ohashi, K; Ishizaki, T
      Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

      PHARMACOGENETICS
    5. Shimada, T; Tsumura, F; Yamazaki, H; Guengerich, FP; Inoue, K
      Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6

      PHARMACOGENETICS
    6. Goldstein, JA
      Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    7. Chow, MSS; White, CM; Lau, CP; Fan, C; Tang, MO
      Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation

      JOURNAL OF CLINICAL PHARMACOLOGY
    8. Dandara, C; Masimirembwa, CM; Magimba, A; Sayi, J; Kaaya, S; Sommers, DK; Snyman, JR; Hasler, JA
      Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    9. Tsao, CC; Wester, MR; Ghanayem, B; Coulter, SJ; Chanas, B; Johnson, EF; Goldstein, JA
      Identification of human CYP2C19 residues that confer S-mephenytoin 4 '-hydroxylation activity to CYP2C9

      BIOCHEMISTRY
    10. Wang, XY; Levy, RH; Ho, RJY
      Development of a semi-quantitative assay to detect full-length CYP2C19 RNA

      BIOTECHNIQUES
    11. Khaliq, Y; Gallicano, K; Seguin, I; Fyke, K; Carignan, G; Bulman, D; Badley, A; Cameron, DW
      Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    12. Ford, GA; Wood, SM; Daly, AK
      CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    13. Bourian, M; Gullsten, H; Legrum, W
      Genetic polymorphism of CYP2A6 in the German population

      TOXICOLOGY
    14. Wedlund, PJ
      The CYP2C19 enzyme polymorphism

      PHARMACOLOGY
    15. O'Neil, WM; Gilfix, BM; Markoglou, N; Di Girolamo, A; Tsoukas, CM; Wainer, IW
      Genotype and phenotype of cytochrome P-450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    16. Lamba, JK; Dhiman, RK; Kohli, KK
      CYP2C19 genetic mutations in North Indians

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    17. Laine, K; Tybring, G; Bertilsson, L
      No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    18. Hijikata, M; Miyakawa, H; Matsushita, M; Kako, M; Ohta, Y; Mishiro, S
      CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    19. Linder, MW; Valdes, R
      Pharmacogenetics in the practice of laboratory medicine

      MOLECULAR DIAGNOSIS
    20. Gaedigk, A; Gotschall, RR; Forbes, NS; Simon, SD; Kearns, GL; Leeder, JS
      Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data

      PHARMACOGENETICS
    21. Dalen, P; Dahl, ML; Eichelbaum, M; Bertilsson, L; Wilkinson, GR
      Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes

      PHARMACOGENETICS
    22. Xie, HG; Stein, CM; Kim, RB; Wilkinson, GR; Flockhart, DA; Wood, AJJ
      Allelic, genotypic and phenotypic distributions of S-mephenytoin 4 '-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world

      PHARMACOGENETICS
    23. Chida, M; Yokoi, T; Kosaka, Y; Chiba, K; Nakamura, H; Ishizaki, T; Yokota, J; Kinoshita, M; Sato, K; Inaba, M; Aoki, Y; Gonzalez, FJ; Kamataki, T
      Genetic polymorphism of CYP2D6 in the Japanese population

      PHARMACOGENETICS
    24. Kaneko, A; Bergqvist, Y; Taleo, G; Kobayakawa, T; Ishizaki, T; Bjorkman, A
      Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations

      PHARMACOGENETICS
    25. Griese, EU; Lapple, F; Eichelbaum, M
      Detection of CYP2C19 alleles*1,*2 and*3 by multiplex polymerase chain reaction

      PHARMACOGENETICS
    26. Marez-Allorge, D; Ellis, SW; Lo Guidice, JM; Tucker, GT; Broly, F
      A rare G(2061) insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype

      PHARMACOGENETICS
    27. Joost, O; Taylor, CA; Thomas, CA; Cupples, LA; Saint-Hilaire, MH; Feldman, RG; Baldwin, CT; Myers, RH
      Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease

      MOVEMENT DISORDERS
    28. Druid, H; Holmgren, P; Carlsson, B; Ahlner, J
      Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results

      FORENSIC SCIENCE INTERNATIONAL
    29. Xie, HG; Kim, RB; Stein, CM; Wilkinson, GR; Wood, AJJ
      Genetic polymorphism of (S)-mephenytoin 4 '-hydroxylation in populations of African descent

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    30. Hamelin, BA; Dorson, PG; Pabis, D; Still, D; Bouchard, RH; Pourcher, E; Rail, J; Turgeon, J; Crismon, ML
      CYP2D6 mutations and therapeutic outcome in schizophrenic patients

      PHARMACOTHERAPY
    31. Coutts, RT; Urichuk, LJ
      Polymorphic cytochromes P450 and drugs used in psychiatry

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    32. Carrillo, JA; Ramos, SI; Herraiz, AG; Llerena, A; Agundez, JAG; Berecz, R; Duran, M; Benitez, J
      Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    33. Tyndale, RF; Li, Y; Li, NY; Messina, E; Miksys, S; Sellers, EM
      Characterization of cytochrome P-450 2D1 activity in rat brain: High-affinity kinetics for dextromethorphan

      DRUG METABOLISM AND DISPOSITION
    34. Norlen, M; Norstrom, A; Spigset, O; Allard, P
      [H-3]GBR 12935 binding in platelets from poor and extensive cytochrome P-4502D6 metabolizers

      EUROPEAN JOURNAL OF PHARMACOLOGY
    35. Tateishi, T; Chida, M; Ariyoshi, N; Mizorogi, Y; Kamataki, T; Kobayashi, S
      Analysis of the C Upsilon P2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    36. Garcia-Barcelo, M; Chow, LY; Chiu, HFK; Wing, YK; Lee, DTS; Lam, KL; Waye, MMY
      Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: Detection of the rare allele CYP2C19*4

      CLINICAL CHEMISTRY
    37. Marsh, JCW; Chowdry, J; Parry-Jones, N; Ellis, SW; Muir, KR; Gordon-Smith, EC; Tucker, GT
      Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia

      BRITISH JOURNAL OF HAEMATOLOGY
    38. van der Weide, J; Steijns, LSW
      Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology

      ANNALS OF CLINICAL BIOCHEMISTRY
    39. Nelson, DR
      Cytochrome P450 and the individuality of species

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    40. SHAW GL; FALK RT; FRAME JN; WEIFFENBACH B; NESBITT JC; PASS HI; CAPORASO NE; MOIR DT; TUCKER MA
      GENETIC-POLYMORPHISM OF CYP2D6 AND LUNG-CANCER RISK

      Cancer epidemiology, biomarkers & prevention
    41. NUNOYA K; YOKOI T; KIMURA K; INOUE K; KODAMA T; FUNAYAMA M; NAGASHIMA K; FUNAE Y; GREEN C; KINOSHITA M; KAMATAKI T
      A NEW DELETED ALLELE IN THE HUMAN CYTOCHROME-P450 2A6 (CYP2A6) GENE FOUND IN INDIVIDUALS SHOWING POOR METABOLIC CAPACITY TO COUMARIN AND (-CIS-3,5-DIMETHYL-2-(3-PYRIDYL)THIAZOLIDIN-4-ONE HYDROCHLORIDE (SM-12502)())

      Pharmacogenetics
    42. GRIESE EU; ZANGER UM; BRUDERMANNS U; GAEDIGK A; MIKUS G; MORIKE K; STUVEN T; EICHELBAUM M
      ASSESSMENT OF THE PREDICTIVE POWER OF GENOTYPES FOR THE IN-VIVO CATALYTIC FUNCTION OF CYP2D6 IN A GERMAN POPULATION

      Pharmacogenetics
    43. YAMAMOTO Y; TASAKI T; NAKAMURA A; IWATA H; KAZUSAKA A; GONZALEZ FJ; FUJITA S
      MOLECULAR-BASIS OF THE DARK AGOUTI RAT DRUG OXIDATION POLYMORPHISM - IMPORTANCE OF CYP2D1 AND CYP2D2

      Pharmacogenetics
    44. Leathart, JBS; London, SJ; Steward, A; Adams, JD; Idle, JR; Daly, AK
      CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles

      PHARMACOGENETICS
    45. DAHL AA; LOWERT A; ASSERSON S; BJARKING L; BERGLUND J; KRISTENSEN F; NORUM D; TONSETH S; BAYER L; MAEHLUM E
      HYDROXYLATION POLYMORPHISM OF DEBRISOQUINE HYDROXYLASE (CYP2D6) IN PATIENTS WITH SCHIZOPHRENIA IN NORWAY AND DENMARK

      Human psychopharmacology
    46. RIEDL AG; WATTS PM; JENNER P; MARSDEN CD
      P450 ENZYMES AND PARKINSONS-DISEASE - THE STORY SO FAR

      Movement disorders
    47. WATANABE M; IWAHASHI K; KUGOH T; SUWAKI H
      THE RELATIONSHIP BETWEEN PHENYTOIN PHARMACOKINETICS AND THE CYP2C19 GENOTYPE IN JAPANESE EPILEPTIC PATIENTS

      Clinical neuropharmacology
    48. KAWANISHI C; SHIMODA Y; FUJIMAKI J; ONISHI H; SUZUKI K; HANIHARA T; SUGIYAMA N; KOSAKA K
      MUTATION INVOLVING CYTOCHROME P450IID6 IN 2 JAPANESE PATIENTS WITH NEUROLEPTIC MALIGNANT SYNDROME

      Journal of the neurological sciences
    49. LO HS; CHEN CH; HOGAN EL; KAO KP; WANG VC; YAN SH
      GENETIC-POLYMORPHISM AND PARKINSONS-DISEASE IN TAIWAN - STUDY OF DEBRISOQUINE 4-HYDROXYLASE (CYP2D6)

      Journal of the neurological sciences
    50. HARTTER S; DINGEMANSE J; BAIER D; ZIEGLER G; HIEMKE C
      INHIBITION OF DEXTROMETHORPHAN METABOLISM BY MOCLOBEMIDE

      Psychopharmacology
    51. CHEN CL; LIU Q; EVANS WE; SANDER CH; RELLING MV
      CYTOCHROME-P450 2D6 AND GLUTATHIONE-S-TRANSFERASE GENOTYPE IN SUDDEN-INFANT-DEATH-SYNDROME

      Journal of paediatrics and child health
    52. MAREZ D; LEGRAND M; SABBAGH N; LOGUIDICE JM; SPIRE C; LAFITTE JJ; MEYER UA; BROLY F
      POLYMORPHISM OF THE CYTOCHROME-P450 CYP2D6 GENE IN A EUROPEAN POPULATION - CHARACTERIZATION OF 48 MUTATIONS AND 53 ALLELES, THEIR FREQUENCIES AND EVOLUTION

      Pharmacogenetics
    53. LOVLIE R; DALY AK; IDLE JR; STEEN VM
      CHARACTERIZATION OF THE 16-KB AND 30+9-KB CYP2D6-XBAI-HAPLOTYPES(9)

      Pharmacogenetics
    54. LOVLIE R; DALY AK; IDLE JR; STEEN VM
      CHARACTERIZATION OF THE 16-KB AND 30+9-KB CYP2D6-XBAI-HAPLOTYPES(9)

      Pharmacogenetics
    55. FROMM MF; KROEMER HK; EICHELBAUM M
      IMPACT OF P450 GENETIC-POLYMORPHISM ON THE FIRST-PASS EXTRACTION OF CARDIOVASCULAR AND NEUROACTIVE DRUGS

      Advanced drug delivery reviews
    56. EVERT B; EICHELBAUM M; HAUBRUCK H; ZANGER UM
      FUNCTIONAL-PROPERTIES OF CYP2D6-1 (WILD-TYPE) AND CYP2D6-7 (HIS(324)PRO) EXPRESSED BY RECOMBINANT BACULOVIRUS IN INSECT CELLS

      Naunyn-Schmiedeberg's archives of pharmacology
    57. MIKUS G; TRAUSCH B; RODEWALD C; HOFMANN U; RICHTER K; GRAMATTE T; EICHELBAUM M
      EFFECT OF CODEINE ON GASTROINTESTINAL MOTILITY IN RELATION TO CYP2D6 PHENOTYPE

      Clinical pharmacology and therapeutics
    58. LINDER MW; PROUGH RA; VALDES R
      PHARMACOGENETICS - A LABORATORY TOOL FOR OPTIMIZING THERAPEUTIC EFFICIENCY

      Clinical chemistry
    59. JURIMAROMET M; FOSTER BC; CASLEY WL; RODE A; VLOSHINSKY P; HUANG HS; GEERTSEN S
      CYP2D6-RELATED OXIDATION POLYMORPHISM IN A CANADIAN INUIT POPULATION

      Canadian journal of physiology and pharmacology
    60. SACHSE C; BROCKMOLLER J; BAUER S; ROOTS I
      CYTOCHROME-P450 2D6 VARIANTS IN A CAUCASIAN POPULATION - ALLELE FREQUENCIES AND PHENOTYPIC CONSEQUENCES

      American journal of human genetics
    61. ANDREASSEN OA; MACEWAN T; GULBRANDSEN AK; MCCREADIE RG; STEEN VM
      NONFUNCTIONAL CYP2D6 ALLELES AND RISK FOR NEUROLEPTICS-INDUCED MOVEMENT-DISORDERS IN SCHIZOPHRENIC-PATIENTS

      Psychopharmacology
    62. STUVEN T; GRIESE EU; KROEMER HK; EICHELBAUM M; ZANGER UM
      RAPID DETECTION OF CYP2D6 NULL ALLELES BY LONG DISTANCE-POLYMERASE AND MULTIPLEX-POLYMERASE CHAIN-REACTION

      Pharmacogenetics
    63. NAKAMURA K; YOKOI T; INOUE K; SHIMADA N; OHASHI N; KUME T; KAMATAKI T
      CYP2D6 IS THE PRINCIPAL CYTOCHROME-P450 RESPONSIBLE FOR THE METABOLISM OF THE HISTAMINE H-1 ANTAGONIST PROMETHAZINE IN HUMAN LIVER-MICROSOMES

      Pharmacogenetics
    64. TAKAKUBO F; KUWANO A; KONDO I
      EVIDENCE THAT POOR METABOLIZERS OF (S)-MEPHENYTOIN COULD BE IDENTIFIED BY HAPLOTYPES OF CYP2C19 IN JAPANESE

      Pharmacogenetics
    65. MASIMIREMBWA C; PERSSON I; BERTILSSON L; HASLER J; INGELMANSUNDBERG M
      A NOVEL MUTANT VARIANT OF THE CYP2D6 GENE (CYP2D6-ASTERISK-17) COMMONIN A BLACK-AFRICAN POPULATION - ASSOCIATION WITH DIMINISHED DEBRISOQUINE HYDROXYLASE-ACTIVITY

      British journal of clinical pharmacology
    66. LUCOTTE G; TURPIN JC; GERARD N; PANSERAT S; KRISHNAMOORTHY R
      MUTATION FREQUENCIES OF THE CYTOCHROME CYP2D6 GENE IN PARKINSON DISEASE PATIENTS AND IN FAMILIES

      American journal of medical genetics
    67. LEGRAND M; STUCKER I; MAREZ D; SABBAGH N; LOGUIDICE JM; BROLY F
      INFLUENCE OF A MUTATION REDUCING THE CATALYTIC ACTIVITY OF THE CYTOCHROME-P450 CYP2D6 ON LUNG-CANCER SUSCEPTIBILITY

      Carcinogenesis
    68. SANDY MS; ARMSTRONG M; TANNER CM; DALY AK; DIMONTE DA; LANGSTON JW; IDLE JR
      CYP2D6 ALLELIC FREQUENCIES IN YOUNG-ONSET PARKINSONS-DISEASE

      Neurology
    69. CHEN SQ; CHOU WH; BLOUIN RA; MAO ZP; HUMPHRIES LL; MEEK C; NEILL JR; MARTIN WL; HAYS LR; WEDLUND PJ
      THE CYTOCHROME-P450 2D6 (CYP2D6) ENZYME POLYMORPHISM - SCREENING COSTS AND INFLUENCE ON CLINICAL OUTCOMES IN PSYCHIATRY

      Clinical pharmacology and therapeutics
    70. LINNET K; WIBORG O
      STEADY-STATE SERUM CONCENTRATIONS OF THE NEUROLEPTIC PERPHENAZINE IN RELATION TO CYP2D6 GENETIC-POLYMORPHISM

      Clinical pharmacology and therapeutics
    71. PANSERAT S; MURA C; GERARD N; VINCENTVIRY M; GALTEAU MM; JACQZAIGRAIN E; KRISHNAMOORTHY R
      AN UNEQUAL CROSS-OVER EVENT WITHIN THE CYP2D GENE-CLUSTER GENERATES ACHIMERIC CYP2D7 CYP2D6 GENE WHICH IS ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPE/

      British journal of clinical pharmacology
    72. AGUNDEZ JAG; JIMENEZJIMENEZ FJ; LUENGO A; BERNAL ML; MOLINA JA; AYUSO L; VAZQUEZ A; PARRA J; DUARTE J; CORIA F; LADERO JM; ALVAREZ JC; BENITEZ J
      ASSOCIATION BETWEEN THE OXIDATIVE POLYMORPHISM AND EARLY-ONSET OF PARKINSONS-DISEASE

      Clinical pharmacology and therapeutics
    73. KERRY NL; SOMOGYI AA; BOCHNER F; MIKUS G
      THE ROLE OF CYP2D6 IN PRIMARY AND SECONDARY OXIDATIVE-METABOLISM OF DEXTROMETHORPHAN - IN-VITRO STUDIES USING HUMAN LIVER-MICROSOMES

      British journal of clinical pharmacology
    74. MAY DG
      GENETIC-DIFFERENCES IN DRUG DISPOSITION

      Journal of clinical pharmacology
    75. EVERT B; GRIESE EU; EICHELBAUM M
      A MISSENSE MUTATION IN EXON-6 OF THE CYP2D6 GENE LEADING TO A HISTIDINE-324 TO PROLINE EXCHANGE IS ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPE OF SPARTEINE

      Naunyn-Schmiedeberg's archives of pharmacology
    76. TUCKER GT; LENNARD MS; ELLIS SW; WOODS HF; CHO AK; LIN LY; HIRATSUKA A; SCHMITZ DA; CHU TYY
      THE DEMETHYLENATION OF METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) BY DEBRISOQUINE HYDROXYLASE (CYP2D6)

      Biochemical pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/10/20 alle ore 00:01:10